N※N

MS Foundation Appoints Teresa Younger as New CEO

  //politics-government.news-articles.net/content/ .. undation-appoints-teresa-younger-as-new-ceo.html
  Published in Politics and Government on Monday, March 16th 2026 at 11:20 GMT by Associated Press
      Locale: UNITED STATES

NEW YORK (March 16th, 2026) - The Multiple Sclerosis (MS) Foundation today announced the appointment of Teresa Younger as its new Chief Executive Officer, effective April 1st, 2026. This leadership transition marks a significant moment for the foundation, poised to build upon a decade of progress under outgoing CEO Nancy E. Andrews and embark on a new chapter focused on accelerating MS research, expanding support services, and championing impactful policy changes.

The appointment of Younger, a highly respected non-profit leader, signals a commitment to both continued scientific advancement and a strengthened focus on equity and access within the MS community. Younger joins the MS Foundation from YWCA USA, where she served as CEO, guiding the organization through significant growth and impact. Her experience leading a national organization dedicated to empowering women and eliminating racism is expected to bring a valuable perspective to the MS Foundation's mission.

"Teresa's track record of success in driving organizational impact, coupled with her deep understanding of social justice and equity issues, makes her the ideal leader to guide the MS Foundation forward," said John K. Anderson, Chairman of the Board, in a press statement. This emphasis on equity is particularly crucial given the documented disparities in access to MS care and the varying impacts of the disease across different populations.

Multiple Sclerosis is a chronic, often disabling disease that affects the central nervous system. It's a complex illness with a wide spectrum of symptoms and severity, impacting quality of life for millions worldwide. The MS Foundation has long been at the forefront of funding critical research aimed at understanding the disease's underlying mechanisms, developing new treatments, and ultimately, finding a cure. Recent research, including advancements in disease-modifying therapies (DMTs), has shown promising results in slowing disease progression and managing symptoms, but a cure remains elusive.

Andrews, who has helmed the MS Foundation for over ten years, leaves a legacy of strategic leadership and focused investment. Under her guidance, the foundation has significantly increased its funding for research projects targeting the diverse facets of MS - from autoimmune responses to neurodegeneration. She also spearheaded initiatives to improve the lives of individuals living with MS, expanding access to support groups, educational resources, and financial assistance. She will continue to contribute to the Foundation's success as a strategic advisor during the transition period, ensuring a seamless handover of leadership.

Younger's arrival comes at a pivotal time for the MS community. While medical advancements offer hope, significant challenges remain. These include the high cost of DMTs, which can be prohibitive for many patients; the need for more effective treatments for progressive forms of MS; and the ongoing struggle to address the psychological and emotional toll of living with a chronic illness. Furthermore, ensuring equitable access to care - particularly for underserved communities and those in rural areas - is a growing priority.

The MS Foundation's strategic plan, as guided by Andrews and now to be further developed under Younger, emphasizes a multi-pronged approach. This includes not only funding innovative research but also advocating for policies that improve access to affordable healthcare, support disability rights, and promote inclusivity. The Foundation also recognizes the importance of empowering individuals with MS to advocate for their own needs and participate in shaping the future of MS care.

"I am incredibly honored and excited to join the MS Foundation and work alongside our dedicated team, volunteers, and advocates to continue advancing our mission," Younger said in a statement. "I believe that by working together, we can accelerate progress towards a world free of MS and ensure that everyone affected by this disease has the opportunity to live a full and meaningful life."

Looking ahead, the MS Foundation under Younger's leadership is expected to explore new avenues for collaboration, including partnerships with other research institutions, pharmaceutical companies, and patient advocacy groups. A greater emphasis on data-driven decision-making and personalized medicine may also be on the horizon, tailoring treatments to the specific needs of each individual with MS. The Foundation will likely continue to champion initiatives promoting early diagnosis and intervention, recognizing that prompt treatment can significantly impact disease progression. The change in leadership promises a future focused on innovation, collaboration, and a deep commitment to the well-being of the MS community.